Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company launched its FDA approved, non-opioid drug Strontium89, which relieves bone pain from cancer metastases, in February 2020. Initial orders to hospitals are being shipped in February, with full commercial scale production and availability expected in March. Strontium89 is also approved for sale in 21 other countries. Q BioMed plans to conduct a Strontium89 Phase IV trial to support a potential label expansion that includes a cancer survival benefit. The Company’s robust clinical pipeline is expected to produce growing revenues for the Company and value infection points for investors.

### Equity Overview (as of February 20, 2020)

- **Ticker:** QBIO
- **Stock Price:** $3.00
- **Shares Outstanding:** 20 M
- **Market Cap:** $69 Million
- **Avg. Trading Volume (90 day):** ~150,000
- **Inside Ownership:** 24%

### Commercialized Product: Non-Opioid Pain Relief for Cancer Patients Whose Cancer Has Metastasized to Bones

**Strontium89**

- **$25 M - $50 M Annual Revenue Potential**
  - FDA approved to treat bone pain from cancer metastases
  - Medicare reimbursed in U.S.
  - Launched in U.S. Q1 2020
  - Plans to launch globally

- **$250 M - $500 M Annual Revenue Potential**
  - Potential to treat metastatic bone cancer
  - Phase IV clinical trials planned to support label extension and cancer survival benefit
  - Competing product generates $800 M/year

### Investment Highlights

#### Launched FDA Approved Drug for Non-Opioid Pain Relief in U.S.

Strontium89 is an FDA approved, non-opioid drug that relieves the severe pain associated with cancer that has metastasized to bone, resulting in a meaningful impact on patients’ lives. An estimated 10 million people are living with bone metastases. Due to the opioid crisis, clinicians and patients are looking for non-opioid alternatives to treat cancer-related pain. Strontium89, which is administered every 3 months, has been shown to relieve pain in over 70% of patients who received the treatment. Q BioMed is hopeful that broad market acceptance will be swift. Initial orders are being delivered to U.S. hospitals in February. Commercial-scale launch is expected in March. Through its distribution agreement with Jubilant Radiopharma, Q BioMed has the capability to reach patients in all 50 states. Strontium89 is reimbursed by Medicare and most health care providers. Strontium89 is anticipated to generate revenues of $25 to $50 million annually in the next 3 years. In the coming quarters, Q BioMed plans to launch the drug in global markets, including Europe.

#### Phase IV Trial for Strontium89 in Treatment of Metastatic Cancer

Based on data published in The Lancet showing Strontium89 extends overall survival, Q BioMed is planning a Phase IV clinical trial for Strontium89 to support a label extension from the current pain palliation into therapeutic use for survival benefit in metastatic bone cancer. This new expanded indication has the potential to generate significant revenues annually. A comparative drug in this therapeutic space was purchased by Bayer for $2.9 billion in 2013, with peak sales projected by Bayer to exceed $1 billion a year.

#### Discovery of Biomarkers for Pediatric Nonverbal Autism Disorder

In a breakthrough, Q BioMed has discovered the first two biomarkers for pediatric nonverbal autism which impacts 18,000 children in the U.S. and 40,000 worldwide. Children with this specific Autism Spectrum Disorder (ASD) are minimally verbal or non-verbal as toddlers. Left untreated, these children will have to rely on assisted living for the rest of their lives, leading to emotional costs for the family as well as an estimated $10 million per person over a lifetime and an annual cost to the healthcare system of $200 billion. Based on the discovery of the biomarkers, Q BioMed has filed an Orphan Drug application with the FDA.

#### Uttroside-B Shown to be 10-X More Potent Against Liver Cancer Cells

Uttroside-B, one of Q BioMed’s preclinical assets, is up to 10 times more potent against liver cancer cells than Sorafenib (based on preclinical data), the leading FDA approved drug for first line treatment of liver cancer. 700,000 people per year are diagnosed with liver cancer, with a very poor 5-year survival rate of 18% due to lack of effective treatments. Q BioMed plans to file an IND with the FDA in 2021 to start a clinical trial in this indication.

#### 7.7 M Grant to Advance Portfolio for Vascular Diseases & Glaucoma

Q BioMed’s research partner, Mannin Research Inc., was recently granted $7.7 million from the German state of Saxony to advance its preclinical pipeline which includes four drug candidates optioned to Q BioMed. The lead candidate, Man-01 is an eye drop treatment for glaucoma that has shown to normalize Intraocular Eye Pressure (IOP). Q BioMed expects to submit an IND application in 2020 to the FDA for this indication which has an addressable market of 80 million patients worldwide.

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are “forward looking” within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements and their implications are based on the current expectations of our management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. A fuller discussion of Q BioMed Inc.’s risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission, which should be reviewed in conjunction with this overview.